Ranolazine in Cardiac Arrhythmia
Marwan Saad1, Ahmed Mahmoud2, Islam Y Elgendy3
1Department of Medicine, Seton Hall University School of Health and Medical Sciences, Trinitas Regional Medical Center, Elizabeth, New Jersey.
Ranolazine effectively manages refractory angina and shows promise for treating cardiac arrhythmias like atrial fibrillation. Ongoing research explores its potential in ventricular arrhythmias, expanding its cardiovascular applications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ranolazine is a well-established treatment for refractory angina.
- Emerging evidence suggests ranolazine has a significant role in managing cardiac arrhythmias.
Purpose of the Study:
- To review the pharmacological, experimental, and clinical evidence for ranolazine in cardiac arrhythmia management.
- To explore the expanding therapeutic potential of ranolazine beyond angina.
Main Methods:
- Review of randomized clinical studies on ranolazine for angina.
- Analysis of experimental and clinical studies investigating ranolazine in atrial and ventricular arrhythmias.
Main Results:
- Ranolazine's efficacy in refractory angina is supported by robust clinical data.
- Studies indicate ranolazine's potential in preventing and managing atrial fibrillation.
- Research is ongoing to determine ranolazine's role in ventricular arrhythmias.
Conclusions:
- Ranolazine is a promising therapeutic agent for various cardiac arrhythmias.
- Further research is warranted to fully elucidate ranolazine's antiarrhythmic properties and clinical utility.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias
